---

Cambridge Neurophysiology Solutions is a trusted provider of professional EEG data science services with over 20 years of experience. We specialize in both clinical and non-clinical EEG analysis, including resting-state and event-related potential (ERP) time series data.

Our team of neurophysiology experts delivers custom solutions in:

• Advanced EEG Data Analysis
• Instrumentation and Lab Design Consulting
• Custom Software Development for EEG Research

What sets us apart? Our services are not only scientifically rigorous but also affordable and scalable to meet the needs of academic labs, clinical research teams, and startups alike.

Whether you're launching a new lab, conducting cognitive research, or developing neurotechnology, we provide the expertise and tools to help you succeed—professionally and cost-effectively.

Cambridge Neurophysiology Solutions – Where Neuroscience Meets Innovation.

About Us

• 

• Elena Morozova M.S.

Elena Morozova, 20 years of expertise in Preclinical Neurophysiology Research, designed and executed in vivo Evoked Potential (EP) and EEG assays as an important measurement of the mechanism of action and/or efficacy of drug candidates for Neurodegeneration, Multiple Sclerosis, ALS, and Neurodevelopmental diseases. Expertise in performing and optimizing EEG recording, custom design of electrodes, and cable systems. Proven success in training for in-vivo procedures, including cannula/electrode implantation surgery for EP and EEG. Effective analytical, communication, and interpersonal skills create an optimal workflow in a fast-paced, data-driven, and results-oriented environment of research teams.




• 

• Dr. Sarah Stankowicz Ph.D.

Dr. Sarah Stankowicz is a translational neuroscientist with over a decade of experience in designing, collecting, analyzing, and transforming neurophysiological data into actionable insights. She served as in vivo lead for multiple modalities (small molecule, antibody, and AAV) in neuroscience programs in multiple disease areas (neurodegenerative, demyelinating, and rare disease). Sarah led the development of preclinical to clinical biomarker strategy for an Alzheimer’s disease target by obtaining and analyzing a multimodal clinical dataset (ADNI). Her analysis of the intersection of genetics, cerebral blood flow, and AD disease progression provided evidence that blood flow should be used as a predictive biomarker in clinical trials. She has since extended this work to use advanced survival attentional AI models to demonstrate that cerebral blood flow in the hippocampus is more predictive of AD progression than combined genetic risk, and that including it in clinical trials improves the predictive power of how individuals will progress by 10-15%. In 2024, Sarah served as the sole invited industry expert at a symposium at Society for Neuroscience on the topic of functional ultrasound, a novel whole-brain, high-resolution blood flow technique she pioneered at Biogen for preclinical to clinical development. In addition to cerebral blood flow, her work on neural and glial activity using fiber photometry, EEG, and AI/ML classification algorithms uncovered novel disease biology for mouse models of multiple sclerosis and rare disease. Sarah is dedicated to developing novel technologies and analysis methods to ensure that data translates into meaningful therapeutic advances for patients suffering from neurological disorders, bridging the gap between preclinical discoveries and clinical applications.




• 

• Dr. Ayan Ghoshal Ph.D.

Dr. Ayan Ghoshal is a translational neuroscientist with 10+ years of experience in drug discovery, biomarker development, and neuropharmacology. Passionate about bridging the gap between preclinical and clinical research, Ayan has led drug development initiatives across neuropsychiatric, rare neurodevelopmental, neurological, and neurodegenerative disorders. His expertise spans multiple therapeutic modalities, including small molecules, gene therapy, biologics, and antisense oligonucleotides (ASOs). A recognized leader in functional brain measurements, Ayan has championed the integration of EEG and ERP into translational and clinical research. His contributions have been instrumental in executing IND-enabling preclinical and biomarker studies, advancing drug targets for CNS disorders. With a deep understanding of R&D transitions, clinical development strategies, and biomarker implementation, Ayan is dedicated to driving innovation in neuroscience to address unmet medical needs.




• 

• Dr. Mihaly Hajos Ph.D., Pharm.D.

Accomplished neurophysiologist with internationally recognized expertise in neurobiology and pharmacology of psychiatric and neurological disorders; extensive research experience and leadership in both academic and industrial drug discovery. Thought leader in translational medicine and CNS biomarkers.




• 

• Dr. Tamas Kiss Ph.D.

Formally trained in physics, Tamás has been working in the field of theoretical neuroscience for two decades. His primary expertise is in the analysis of multimodal neurophysiological data as well as modeling biologically realistic neural networks. Currently Tamás works in the Theoretical Neuroscience and Complex Systems Group at Wigner RCP of the Hungarian Academy of Sciences. Recently, he started his experimental laboratory at Semmelweis University conducting electrophysiological and behavioral experiments supported by Gedeon Richter Plc. Tamás is primarily interested in the translational aspects of sleep and sleep-related electrophysiological phenomena for the understanding of psychiatric disorders.